These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 32838757

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop.
    Grünert SC, Derks TGJ, Mundy H, Dalton RN, Donadieu J, Hofbauer P, Jones N, Uçar SK, LaFreniere J, Contreras EL, Pendyal S, Rossi A, Schneider B, Spiegel R, Stepien KM, Wesol-Kucharska D, Veiga-da-Cunha M, Wortmann SB.
    Mol Genet Metab; 2024 Mar; 141(3):108144. PubMed ID: 38277989
    [Abstract] [Full Text] [Related]

  • 3. Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.
    Shao YX, Liang CL, Su YY, Lin YT, Lu ZK, Lin RZ, Zhou ZZ, Zeng CH, Tao CY, Liu ZC, Zhang W, Liu L.
    Orphanet J Rare Dis; 2024 Apr 11; 19(1):155. PubMed ID: 38605407
    [Abstract] [Full Text] [Related]

  • 4. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.
    Wortmann SB, Van Hove JLK, Derks TGJ, Chevalier N, Knight V, Koller A, Oussoren E, Mayr JA, van Spronsen FJ, Lagler FB, Gaughan S, Van Schaftingen E, Veiga-da-Cunha M.
    Blood; 2020 Aug 27; 136(9):1033-1043. PubMed ID: 32294159
    [Abstract] [Full Text] [Related]

  • 5. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre.
    Halligan RK, Dalton RN, Turner C, Lewis KA, Mundy HR.
    Orphanet J Rare Dis; 2022 May 12; 17(1):195. PubMed ID: 35549996
    [Abstract] [Full Text] [Related]

  • 6. Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial.
    Li Z, Zhang X, Chen H, Zeng H, Wu J, Wang Y, Ma N, Lan J, Zhang Y, Niu H, Shang L, Jiang X, Yang M.
    Sci Rep; 2024 Apr 15; 14(1):8630. PubMed ID: 38622211
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Case report: The success of empagliflozin therapy for glycogen storage disease type 1b.
    Klinc A, Groselj U, Mlinaric M, Homan M, Markelj G, Mezek Novak A, Sirca Campa A, Sikonja J, Battelino T, Zerjav Tansek M, Drole Torkar A.
    Front Endocrinol (Lausanne); 2024 Apr 15; 15():1365700. PubMed ID: 38919482
    [Abstract] [Full Text] [Related]

  • 9. Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment.
    Tallis E, Karsenty CL, Grimes AB, Karam LB, Elsea SH, Sutton VR, Rawls-Castillo BL, Liu N, Soler-Alfonso C.
    JIMD Rep; 2022 Jul 15; 63(4):309-315. PubMed ID: 35822097
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b.
    Grünert SC, Gautschi M, Baker J, Boyer M, Burlina A, Casswall T, Corpeleijn W, Çıki K, Cotter M, Crushell E, Derks TGJ, Haas D, Kilavuz S, Kingma SDK, Korman SH, Kozek A, de Laet C, Mundy H, Nassogne MC, Quintero V, Rossi A, Spenger J, Spiegel R, Stephenne X, Stojkov D, Tal G, Veiga-da Cunha M, Wortmann SB.
    Mol Genet Metab; 2024 Jun 15; 142(2):108486. PubMed ID: 38733639
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
    Maiorana A, Tagliaferri F, Dionisi-Vici C.
    Front Endocrinol (Lausanne); 2023 Jun 15; 14():1145111. PubMed ID: 37152929
    [Abstract] [Full Text] [Related]

  • 14. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib.
    Grünert SC, Rosenbaum-Fabian S, Schumann A, Selbitz AC, Merz W, Gieselmann A, Spiekerkoetter U.
    JIMD Rep; 2022 Jul 15; 63(4):303-308. PubMed ID: 35822091
    [Abstract] [Full Text] [Related]

  • 15. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5.
    Boulanger C, Stephenne X, Diederich J, Mounkoro P, Chevalier N, Ferster A, Van Schaftingen E, Veiga-da-Cunha M.
    J Inherit Metab Dis; 2022 Jul 15; 45(4):759-768. PubMed ID: 35506446
    [Abstract] [Full Text] [Related]

  • 16. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I.
    Visser G, Rake JP, Fernandes J, Labrune P, Leonard JV, Moses S, Ullrich K, Smit GP.
    J Pediatr; 2000 Aug 15; 137(2):187-91. PubMed ID: 10931410
    [Abstract] [Full Text] [Related]

  • 17. Partial correction of neutrophil dysfunction by oral galactose therapy in glycogen storage disease type Ib.
    Letkemann R, Wittkowski H, Antonopoulos A, Podskabi T, Haslam SM, Föll D, Dell A, Marquardt T.
    Int Immunopharmacol; 2017 Mar 15; 44():216-225. PubMed ID: 28126686
    [Abstract] [Full Text] [Related]

  • 18. Repurposing of Empagliflozin as a Possible Treatment for Neutropenia and Inflammatory Bowel Disease in Glycogen Storage Disease Type Ib: A Case Report.
    Makrilakis K, Barmpagianni A, Veiga-da-Cunha M.
    Cureus; 2022 Jul 15; 14(7):e27264. PubMed ID: 36039216
    [Abstract] [Full Text] [Related]

  • 19. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.
    Dale DC, Bolyard AA, Marrero T, Kelley ML, Makaryan V, Tran E, Leung J, Boxer LA, Kishnani PS, Austin S, Wanner C, Ferrecchia IA, Khalaf D, Maze D, Kurtzberg J, Zeidler C, Welte K, Weinstein DA.
    Curr Opin Hematol; 2019 Jan 15; 26(1):16-21. PubMed ID: 30451720
    [Abstract] [Full Text] [Related]

  • 20. Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin.
    Kaczor M, Malicki S, Folkert J, Dobosz E, Bryzek D, Chruscicka-Smaga B, Greczan M, Wesół-Kucharska D, Piątosa B, Samborowska E, Madzio J, Książyk J, Ehmke Vel Emczyńska E, Hajdacka M, Potempa J, Młynarski W, Rokicki D, Veillard F.
    Blood Adv; 2024 Jun 11; 8(11):2790-2802. PubMed ID: 38531056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.